BridgeBio Pharma, Inc. (BBIO)

Market Cap	13.25B +102.8%
Revenue (ttm)	502.08M +126.3%
Net Income	-724.93M
EPS	-3.78
Shares Out	193.86M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	929,386
Open	70.35
Previous Close	71.39
Day's Range	67.85 - 70.36
52-Week Range	28.33 - 84.94
Beta	1.18
Analysts	Strong Buy
Price Target	83.00 (+21.45%)
Earnings Date	Apr 28, 2026

About BBIO

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 27, 2019
• Employees: 839
• Stock Exchange: NASDAQ
• Ticker Symbol: BBIO
• Website: https://bridgebio.com

Financial Performance

In 2025, BridgeBio Pharma's revenue was $502.08 million, an increase of 126.26% compared to the previous year's $221.90 million. Losses were -$724.93 million, 35.3% more than in 2024.

Analyst Summary

According to 24 analysts, the average rating for BBIO stock is "Strong Buy." The 12-month stock price target is $83.0, which is an increase of 21.45% from the latest price.

Price Target

$83.0

(21.45% upside)

Analyst Consensus: Strong Buy